RxDoctor Payments Data

Gregory Singer, MD

Cardiovascular Disease · Rochester, NYNPI 1114010865

Payments from drug & device makers

$84,842in general payments, 2019–2025

Across 188 payments — averaging $451.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$63K
  • Amgen$19K
  • Sanofi-aventis U.S. LLC$1K
  • E.r. Squibb & Sons, L.L.C.$713
  • Novartis$463
  • Medtronic$314
  • plus $341 from 3 others

What the payments were for

  • Consulting fees$1,4382%
  • Speaking & faculty fees$76,70790%
  • Travel & lodging$2,5413%
  • Food & beverage$3,9645%
  • Education$320%
  • Other$1620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson67$62,856
Amgen26$18,965
Sanofi-aventis U.S. LLC3$1,190
E.r. Squibb & Sons, L.L.C.53$713
Novartis25$463
Medtronic(2 entities)10$314
Abbott2$166
Welch Allyn1$162
Pfizer1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,842 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$191,934
Medicare patients
303
Services billed
2,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,131$1,321,219
XareltoRivaroxaban251$316,235
EntrestoSacubitril/Valsartan214$242,655
MultaqDronedarone Hcl140$174,119
JardianceEmpagliflozin78$73,244
Dofetilide112$48,459
Repatha SureclickEvolocumab38$33,758
FarxigaDapagliflozin Propanediol30$27,509
Metoprolol Succinate1,433$24,844
Repatha PushtronexEvolocumab27$19,195
Ranolazine ErRanolazine133$16,531
Amlodipine Besylate1,484$12,347
Atorvastatin Calcium685$11,299
Losartan Potassium864$11,294
ClopidogrelClopidogrel Bisulfate786$10,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$1,321,2191,131 claims
Johnson & JohnsonXarelto$62,856$316,235251 claims
NovartisEntresto$463$242,655214 claims
Sanofi-aventis U.S. LLCMultaq$1,190$174,119140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →